Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Are high drug prices for hematologic malignancies justified? A critical analysis

12 references·1 citing·44 second hop

FromToDepth

this work references cited by second hop

References

1996The Role of Cost-effectiveness Analysis in Health and Medicine1,277 cited
2013The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience1,160 cited
1994Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine871 cited
2014Income and Poverty in the United States: 2013658 cited
2013The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts592 cited
2013Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia500 cited
2015Pricing in the Market for Anticancer Drugs452 cited
2015Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?115 cited
2014High Cancer Drug Prices in the United States: Reasons and Proposed Solutions114 cited
2000Pharmacoeconomic Analyses107 cited
2004Cost‐effectiveness of imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia78 cited
2005Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma60 cited

Cited by

2015Necitumumab in Metastatic Squamous Cell Lung Cancer

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

48 cited